Peptide Tools to Study SARS-CoV-2 and Its Variants

At JPT, we have launched an extensive development program that provides researchers with a wide range of SARS-CoV-2 peptide tools and various COVID research products. These tools are designed for various applications, including immune monitoring, cross-reactivity evaluation, and diagnostics. In addition to SARS-CoV-2, we now offer peptide products targeting other coronaviruses, such as SARS-CoV, MERS-CoV, and common cold viruses. Explore the full spectrum of our peptide tools and products below!

Applications of SARS-CoV-2 Peptide Tools

Our SARS-CoV-2 peptide pools offer a powerful resource for scientific and clinical research. These SARS-CoV-2 research products have been curated to support critical applications, such as:

SARS-CoV-2 Clinical Trial Immune Monitoring
Our peptides enable the monitoring of immune responses in clinical trials, helping researchers understand the impact of vaccines and therapies on SARS-CoV-2 immunity.
SARS-CoV-2 Cross-Reactivity Evaluation
Evaluate the cross-reactivity of SARS-CoV-2 peptides with other viruses, including common cold coronaviruses and other viral infections, to better understand immune responses and potential cross-protection.
SARS-CoV-2 Blood and Serological Test Development
Leverage our COVID-19 peptides for the development of reliable blood and serological tests. These peptides are essential in detecting antibodies and monitoring the immune response in infected and vaccinated individuals.
SARS-CoV-2 T-Cell and B-Cell Epitope Discovery
Identify and map T-cell and B-cell epitopes using our comprehensive SARS-CoV-2 peptide pools, accelerating research into the immune system’s response to COVID-19 and its variants.

We have broadened our portfolio of coronavirus related products beyond SARS-CoV-2, including SARS-CoV, MERS-CoV and common cold viruses CoV 229E, OC43, HKU1 and NL63. Have a look below!

Overview of Spike Glycoprotein Mutations Flyer: Covid-19 Peptide Tools

Expanding Beyond SARS-CoV-2: Peptides for Other Coronaviruses

In response to the global pandemic, we have expanded our peptide portfolio to include not only SARS-CoV-2 but also other notable coronaviruses:

SARS-CoV Peptides
Peptides spanning the genome of the original SARS-CoV are now available to support comparative studies and the evaluation of cross-reactivity with SARS-CoV-2.
MERS-CoV Peptide Pools
Explore our MERS-CoV peptides for research into Middle East Respiratory Syndrome, providing a deeper understanding of its pathogenesis and immune responses.
Common Cold Coronavirus Peptides
Our peptide tools now encompass common cold viruses, including 229E, OC43, HKU1, and NL63, enabling researchers to investigate immunity and cross-reactivity between COVID-19 and less severe coronaviruses.

Advancing Research with High-Quality SARS-CoV-2 Peptide Pools

Our high-quality SARS-CoV-2 peptide pools cover the full genome, allowing for comprehensive analysis of the virus's structure, mutation variants, and immune response targets. These peptide tools are indispensable for researchers focused on vaccine development, therapeutic strategies, and diagnostics in the fight against COVID-19.

JPT's SARS-CoV-2 Peptide Formats

Cellular Immunity

PepMix™ Peptide Pools

Antigen-specific T-cell stimulation
Cellular immune monitoring
Vaccine target discovery
Blood test development
Cross reactivity testing (SARS-CoV-2 vs. SARS, MERS, HCoV 229E, OC43…)
Cell therapy development

Epitope Mapping Peptide Sets (EMPS)

Efficient epitope mapping and identification
Matrix Pools and individual peptides spanning a whole antigen in one set
Minimal sample amount required

Antigen Peptides

Antigen specific T-cell stimulation in T-cell assays (i.e. ELISpot, ICS)
Immune monitoring
Proliferation assays
T-cell expansion

Humoral Immunity

PepStar™ Peptide Microarrays

Humoral immune monitoring
Antibody epitope discovery
Cross reactivity testing (SARS-CoV-2 vs. SARS, MERS, HCoV 229E, OC43…)
Seromarker discovery
PepStar™ Antigen Collection Pan-Coronavirus for cross reactivity testing with SARS-CoV-2 vs. SARS, MERS, HCoV 229E, OC43…)
PepStar™ Peptide Microarrays for individual SARS-CoV-2 and SARS-CoV antigens
Custom PepStar™ Peptide Microarrays

You define content and layout, we provide economic and fast production in our regulated clean-room environment. We also offer our assay and analysis service using your samples with your tailored peptide microarray.

Antibody Response Profiling

Thousands of peptides spanning the entire SARS-CoV-2 genome using smallest sample volumes
Incubation using smallest sample volumes
Study of antibody cross-reactivities between SARS-CoV-2 and other corona viruses
Verification of peptide binders with a large numbers of samples
Transfer of results to ELISA platform for rapid test development

Peptide ELISA

Peptide ELISA development and service using SARS-CoV-2 peptides or a combination with other corona viruses
ELISA-based validation service of peptide binders identified by using JPT’s peptide microarray platform
Collaborative ELISA test development

Clinical Immune Monitoring & Cell Therapy

Clinical Grade Peptides & PepMix™ Peptide Pools

High quality chemically synthesized antigen source for vaccine trial monitoring
Ancillary reagents for cellular therapy development
Full analytical coverage, stability testing, batch documentation and more

Proteomics

SpikeMix™ SARS-CoV-2

Identify SARS CoV-2 antigens from biological samples
Mass spectrometry based assays (MRM)
Screen 23 proteotypic peptides from SARS-CoV-2

Find SARS-CoV-2 Peptide variants

Alpha B.1.1.7

WHO Designation
Variant of Concern

First Publication
Investigation of novel SARS-COV-2 variant: Variant of Concern
Chand et al, Public Health England (2020)

GISAID Accession ID
EPI_ISL_601443
EPI_ISL_581117

JPT’s products

Mutations:
H0069-; V0070-; Y0144-; N0501Y; A0570D; D0614G; P0681H; T0716I; S0982A; D1118H

These mutations characterize approx. 86.8 % of all sequences in the B.1.1.7 lineage. Variants pertaining to Alpha may include these additional mutations:
L0005F, V0006A, S0012F, L0018F, T0020I, R0021T, T0022I, H0049Y, A0067S, A0067V, S0071F, T0076I, P0082L, S0094F, T0095I, E0096D, S0098F, R0102I, D0138H, V0143F, H0146Q, S0151G, W0152R, L0176F, E0180G, R0214L, D0215Y, L0216F, S0221L, A0222V, H0245Y, S0255F, G0261A, A0262-, D0287G, V0289I, T0299I, T0307I, V0308L, T0323I, N0354D, N0394Y, A0475V, E0484K, S0494P, T0572I, A0575S, E0583D, V0622F, A0623S, A0626T, S0640F, Q0675H, Q0677H, T0678I, S0680F, P0681R, A0688V, A0701V, A0706V, T0732I, M0740V, R0765C, P0812S, I0818V, A0831V, K0835R, A0879V, A0892V, I0909V, L0938F, S0939F, G0946V, A1020V, V1129I, E1188D, K1191N, I1227M, V1228L, M1237I, C1243F, P1263L

Beta B.1.351

WHO Designation
Variant of Concern

First Publication
Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa
Tegally et al, Medrxiv (2020)

GISAID Accession ID
EPI_ISL_700428

JPT’s products

Mutations:
D0080A, D0215G, L0242-, A0243-, L0244-, K0417N, E0484K, N0501Y, D0614G, A0701V This variant is annotated in the GISAID database 2008 times. An additional variant with the L18F mutation is described 1769 times. (June 13, 2021)

Gamma P.1

WHO Designation
Variant of Concern

First Publication
Brief report: New Variant Strain of SARS-CoV-2 Identified in Travelers from Brazil National Institute of Infectious Diseases Japan (2021)

JPT's products

Mutations:
L0018F, T0020N, P0026S, D0138Y, R0190S, K0417T, E0484K, N0501Y, D0614G, H0655Y, T1027I, V1176F

Delta B.1.617.2

WHO Designation
Variant of Concern

First Publication
Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India.
Cherian et al, BioRxiv (2021)

GISAID Accession ID
EPI_ISL_1969243

JPT’s products

Mutations:
T0019R; G0142D, E0156-, F0157-, R0158G, L0452R, T0478K, D0614G, P0681R, D0950N

Epsilon B.1.429

WHO Designation
Formerly Monitored Variant

First Publication
Emergence of a Novel SARS-CoV-2 Variant in Southern California.
Zhang et al, JAMA (2021)

GISAID Accession ID
EPI_ISL_755187

JPT’s products

Mutations:
S0013I, W0152C, L0452R, D0614G

Kappa B.1.617.1

WHO Designation
Formerly Monitored Variant

First Publication
Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India.
Cherian et al, BioRxiv (May 2021)

GISAID Accession ID
EPI_ISL_1372093

JPT’s products

Mutations:
T0095I, G0142D, E0154K, L0452R, E0484Q, D0614G, P0681R, Q1071H

Lambda C.37

WHO Designation
Variant of Interest

First Publication
COVID-19 Weekly Epidemiological Update. Edition 44 (2021)

GISAID Accession ID
EPI_ISL_2158693

JPT’s products

Mutations:
G0075V; T0076I; RSYLTPGD0246-0253N (R0246-; S0247-; Y0248-; L0249-; T0250-; P0251-; G0252-; D0253N); L0452Q; F0490S; D0614G; T0859N

Omicron BA.1

WHO Designation
Variant of Concern

First Publication
Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern

GISAID Accession ID
EPI_ISL_6752027

JPT’s products

Mutations:
A0067V; H0069del; V0070del; T0095I; G0142D; V0143del; Y0144del; Y0145del; N0211I*; L0212V*; V0213R*; R0214EPE*; G0339D; S0371L; S0373P; S0375F; K0417N; N0440K; G0446S; S0477N; T0478K; E0484A; Q0493R; G0496S; Q0498R; N0501Y; Y0505H; T0547K; D0614G; H0655Y; N0679K; P0681H; N0764K; D0796Y; N0856K; Q0954H; N0969K; L0981F

Omicron BA.2

WHO Designation
Variant of Concern

First Publication
Virological characteristics of SARS-CoV-2 BA.2 variant & BA.5 in South Africa
Yamasoba et al., (2022)

GISAID Accession ID
EPI_ISL_8459223

JPT’s products

PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.2 / Omicron)
PepMix SARS-CoV-2 (S-RBD B.1.1.529 / BA.2 / Omicron)
PepMix SARS-CoV-2 (NCAP B.1.1.529 / BA.1 / Omicron) (1 aa difference to BA.2)
PepMix SARS-CoV-2 (VEMP B.1.1.529 / BA.1 / Omicron) (no difference)
PepMix SARS-CoV-2 (VME1 B.1.1.529 / BA.1 / Omicron) (1 aa difference to BA.2)

Mutations:
T0019I; L0024-; P0025-; P0026-; A0027S; G0142D; V0213G; G0339D; S0371F; S0373P; S0375F; T0376A; D0405N; R0408S; K0417N; N0440K; S0477N; T0478K; E0484A; Q0493R; Q0498R; N0501Y; Y0505H; D0614G; H0655Y; N0679K; P0681H; N0764K; D0796Y; Q0954H; N0969K

Omicron BA.4/5

WHO Designation
Variant of Concern

First Publication
Emergence of SARS-CoV-2 Omicron lineages BA.4 & BA.5 in South Africa
Tegally et al., (2022)

GISAID Accession ID
EPI_ISL_12688263

JPT’s products
PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.4/5 / Omicron) Entire Spike Protein
PepMix SARS-CoV-2 (S-RBD B.1.1.529 / BA.4/5 / Omicron) Spike Receptor Binding Domain

Mutations:
T0019I, L0024-, P0025-, P0026-, A0027S, H0069-, V0070-, G0142D, V0213G, G0339D, S0371F, S0373P, S0375F, T0376A, D0405N, R0408S, K0417N, N0440K, L0452R, S0477N, T0478K, E0484A, F0486V, Q0498R, N0501Y, Y0505H, D0614G, H0655Y, N0679K, P0681H, N0764K, D0796Y, Q0954H, N0969K

Omicron BA.2.75

WHO Designation
Variant under Monitoring

GISAID Accession ID
EPI_ISL_13392500

JPT’s products
PepMix SARS-CoV-2 (Spike BA.2.75 / Omicron) Entire Spike Protein
PepMix SARS-CoV-2 (S-RBD BA.2.75 / Omicron) Spike Receptor Binding Domain

Mutations:
T0019I, L0024-, P0025-, P0026-, A0027S, G0142D, K0147E, W0152R, F0157L, I0210V, V0213G, G0257S, G0339H, S0371F, S0373P, S0375F, T0376A, D0405N, R0408S, K0417N, N0440K, G0446S, N0460K, S0477N, T0478K, E0484A, Q0498R, N0501Y, Y0505H, D0614G, H0655Y, N0679K, P0681H, N0764K, D0796Y, Q0954H, N0969K

Omicron BA.2.75.2

WHO Designation
Variant under Monitoring

GISAID Accession ID
EPI_ISL_15104931

JPT’s products

PepMix SARS-CoV-2 (Spike BA.2.75.2 / Omicron)
PepMix SARS-CoV-2 (S-RBD BA.2.75.2 / Omicron)

Mutations:
T0019I, L0024-, P0025-, P0026-, A0027S, G0142D, K0147E, W0152R, F0157L, I0210V, V0213G, G0257S, G0339H, R0346T, S0371F, S0373P, S0375F, T0376A, D0405N, R0408S, K0417N, N0440K, G0446S, N0460K, S0477N, T0478K, E0484A, F0486S, Q0498R, N0501Y, Y0505H, D0614G, H0655Y, N0679K, P0681H, N0764K, D0796Y, Q0954H, N0969K, D1199N

Omicron BF.7

WHO Designation
Variant under Monitoring

GISAID Accession ID
EPI_ISL_13183136

JPT’s products

Mutations:
T0019I, L0024-, P0025-, P0026-, A0027S, H0069-, V0070-, G0142D, V0213G, G0339D, R0346T, S0371F, S0373P, S0375F, T0376A, D0405N, R0408S, K0417N, N0440K, L0452R, S0477N, T0478K, E0484A, F0486V, Q0498R, N0501Y, Y0505H, D0614G, H0655Y, N0679K, P0681H, N0764K, D0796Y, Q0954H, N0969K

Omicron BQ.1.1

WHO Designation
Variant under Monitoring

GISAID Accession ID
EPI_ISL_14818139

JPT’s products

Mutations:
T0019I, L0024-, P0025-, P0026-, A0027S, H0069-, V0070-, G0142D, V0213G, G0339D, R0346T, S0371F, S0373P, S0375F, T0376A, D0405N, R0408S, K0417N, N0440K, K0444T, L0452R, N0460K, S0477N, T0478K, E0484A, F0486V, Q0498R, N0501Y, Y0505H, D0614G, H0655Y, N0679K, P0681H, N0764K, D0796Y, Q0954H, N0969K

Omicron XBB.1.5

WHO Designation
Variant under Monitoring

First Publication
Enhanced transmissibility of XBB.1.5 is contributed by both strong ACE2 binding and antibody evasion
Yue et al., BioRxiv (2023)

GISAID Accession ID
EPI_ISL_15687648

JPT’s products

Mutations
T0019I, L0024-, P0025-, P0026-, A0027S, D0080A, G0142D, Y0144-, H0146Q, Q0183E, V0213E, G0252V, G0339H, R0346T, L0368I, S0371F, S0373P, S0375F, T0376A, D0405N, R0408S, K0417N, N0440K, V0445P, G0446S, N0460K, S0477N, T0478K, E0484A, F0486P, F0490S, Q0498R, N0501Y, Y0505H, D0614G, H0655Y, N0679K, P0681H, N0764K, D0796Y, Q0954H, N0969K

Omicron EG.5.1

WHO Designation
Variant of Interest

First Publication
Editorial: A Rapid Global Increase in COVID-19 is Due to the Emergence of the EG.5 (Eris) Subvariant of Omicron SARS-CoV-2
Parums et al., Med.Sci.Monit. (2023)

GISAID Accession ID
EPI_ISL_17432511

JPT’s products

Mutations
T0019I, L0024-, P0025-, P0026-, A0027S, Q0052H, D0080A, G0142D, Y0144-, H0146Q, Q0183E, V0213E, G0252V, G0339H, R0346T, L0368I, S0371F, S0373P, S0375F, T0376A, D0405N, R0408S, K0417N, N0440K, V0445P, G0446S, F0456L, N0460K, S0477N, T0478K, E0484A, F0486P, F0490S, Q0498R, N0501Y, Y0505H, D0614G, H0655Y, N0679K, P0681H, N0764K, D0796Y, Q0954H, N0969K

Omicron BA.2.86

WHO Designation
Variant of Interest

First Publication
Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants
Qu et al., BioRxiv (2023)

GISAID Accession ID
EPI_ISL_18096761

JPT’s products

Mutations
+0016MPLF, T0019I, R0021T, L0024-, P0025-, P0026-, S0050L, Q0052H, H0069-, V0070-, D0080A, V0127F, G0142D, Y0144-, F0157S, R0158G, Q0183E, N0211-, L0212I, V0213G, L0216F, H0245N, A0264D, I0332V, G0339H, K0356T, S0371F, S0373P, S0375F, T0376A, D0405N, K0417N, N0440K, V0445H, G0446S, N0450D, L0452W, N0460K, S0477N, T0478K, N0481K, V0483-, E0484K, F0486P, Q0498R, N0501Y, Y0505H, A0570V, D0614G, P0621S, H0655Y, I0670V, N0679K, P0681R, N0764K, D0796Y, S0939F, Q0954H, N0969K, P1143L

Omicron JN.1

WHO Designation

Variant of Interest

First Publication
Virological characteristics of the SARS-CoV-2 JN.1 variant.
Kaku et al., BioRxiv (2023)

GISAID Accession ID
EPI_ISL_18530042

JPT’s products

PepMix SARS-CoV-2 (Spike JN.1)
PepMix SARS-CoV-2 (S-RBD JN.1): w/o R408S, E554K, incl. I670V
PepMix SARS-CoV-2 (Spike JN.1 v2): incl. R408S, E554K, w/o I670V

Mutations
+0016MPLF, T0019I, R0021T, L0024-, P0025-, P0026-, S0050L, Q0052H, H0069-, V0070-, D0080A, V0127F, G0142D, Y0144-, F0157S, R0158G, Q0183E, N0211-, L0212I, V0213G, L0216F, H0245N, A0264D, I0332V, G0339H, K0356T, S0371F, S0373P, S0375F, T0376A, D0405N, (R408S), K0417N, N0440K, V0445H, G0446S, N0450D, L0452W, L455S, N0460K, S0477N, T0478K, N0481K, V0483-, E0484K, F0486P, Q0498R, N0501Y, Y0505H, (E554K), A0570V, D0614G, P0621S, H0655Y, (I0670V), N0679K, P0681R, N0764K, D0796Y, S0939F, Q0954H, N0969K, P1143L

Publications

References 2024

Alphaviral genetic background of self-amplifying RNA enhances protein expression and immunogenicity against SARS-CoV-2 antigen
Casmil et al., Molecular Therapy (2024)
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
Comparison of a SARS-CoV-2 mRNA booster immunization containing additional antigens to a spike-based mRNA vaccine against Omicron BA.5 infection in hACE2 mice
Hurst et al., PLoS One (2024) - PMID: 39625929
Product used: PepMix™ SARS-CoV-2 (Spike B.1.351 / Beta)
T Cell Responses to BA.2.86 and JN.1 SARS-CoV-2 Variants in Elderly Subjects
Segato et al., Vaccines (2024)
Products used: PepMix™ SARS-CoV-2 (S-RBD), PepMix™ SARS-CoV-2 (S-RBD BA.2.86)
Effect of XBB.1.5-adapted booster vaccination on the imprinting of SARS-CoV-2 immunity
Pušnik et al., Vaccines (2024) - PMID: 39572559
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), PepMix™ SARS-CoV-2 (Spike XBB.1.5)
Adjuvants to the S1-subunit of the SARS-CoV-2 spike protein vaccine improve antibody and T cell responses and surrogate neutralization in mice
Becker et al., Scientific Reports (2024)
Product used: PepMix™ SARS-CoV-2 (S-RBD)
Antibodies in Infectious Diseases: HIV Biomarker Discoveries, Complement Enhanced SARS-CoV-2 Neutralization and Vaccine Generation
Buylowski et al., Dissertation (2024)
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
Suppression of Type I Interferon Signaling in Myeloid Cells by Autoantibodies in Severe COVID‑19 Patients
Aoki et al., Journal of Clinical Immunology (2024) - PMID: 38647550
Products used: Custom PepStar
Autoantibodies to ACE2 and immune molecules are associated with COVID-19 disease severity
Geanes et al., Communications Medicine (2024) - PMID: 38491326
Product used: Custom PepStar
Antigen clustering effect on immunogenicity in prefusion-stabilized spike-based COVID-19 vaccines
Matthews et al., Research Square (2024)
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1)
Engineered protein subunit COVID19 vaccine is as immunogenic as nanoparticles in mouse and hamster models
Matthews et al., Scientific Reports (2024)
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
A Robust SARS-CoV-2-specific T and B Cell Response is Associated with Early Viral Clearance in SARS-CoV-2 Infected Immunocompromised Individuals
Vergouwe et al., Journal of Infectious Diseases (2024) - PMID: 38843052
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), PepMix™ SARS-CoV-2 (NCAP)
Immunogenicity and Protective Efficacy of Psoralen-Inactivated SARS-CoV-2 Vaccine in Nonhuman Primates
Sanders et al., Vaccines (2024)
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
A multiantigenic Orf virus-based vaccine efficiently protects hamsters and nonhuman primates against SARS-CoV-2
Reguzova et al., NPJ Vaccines (2024) - PMID: 39414789
Products used: PepMix™ SARS-CoV-2 (NCAP), PepMix™ SARS-CoV-2 (Spike Glycoprotein)
Cellular and humoral response to SARS-CoV-2 vaccine BNT162b2 in adults with Chronic Kidney Disease G4/5.
Rosdahl et al., New Microbes & New Infections (2024) - PMID: 39282145
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA. 1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses
Pérez et al., Frontiers in Immunology (2024) - PMID: 39267752
Product used: PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
SARS-CoV-2 spike-specific nasal-resident CD49a+CD8+ memory T cells exert immediate effector functions with enhanced IFN-γ production
Rha et al., Nature Communications (2024) - PMID: 39333516
Product used: PepMix™ SARS-CoV-2 (NCAP)
Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways
Gagne et al., Nature Communications (2024) - PMID: 39134521
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates
Gagne et al., Nature Immunology (2024) - PMID: 39227514
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), PepMix™ SARS-CoV-2 (NCAP)
Endurance Exercise Does Not Exacerbate Cardiac Inflammation in BALB/c Mice Following mRNA COVID-19 Vaccination
Eens et al., Vaccines (2024)
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
Asian Flush Gene Variant Enhances Cellular Immunogenicity of COVID‐19 Vaccine: Prospective Study in the Japanese General Population
Bogahawaththa et al., Vaccines (2024)
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
Heterologous mRNA/MVA delivering trimeric-RBD as effectivevaccination regimen against SARS-CoV-2: COVARNA Consortium
Marcos-Villar et al., Emerging Microbes & Infections
Product used: PepMix™ SARS-CoV-2 (S-RBD)
Interleukin‐2‐mediated CD4 T‐cell activation correlates highly with effective serological and T‐cell responses to SARS‐CoV‐2 vaccination in people living with HIV
Gupta et al., Journal of Medical Virology (2024) - PMID: 39056205
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
Cytokine profile of anti-spike CD4+ T cells predicts humoral and CD8+ T cell responses after anti-SARS-CoV-2 mRNA vaccination
Benhamouda et al., iScience (2024)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
Repeated COVID-19 Vaccination Drives Memory T- and B-cell Responses in Kidney Transplant Recipients: Results From a Multicenter Randomized Controlled Trial
Malahe et al., Transplantation (2024)
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
Kinetics of pro- and anti-infammatory spike-specifc cellular immune responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: a prospective longitudinal study in Japan
Kagugawa et al., Immunity and Ageing (2024) - PMID: 38909235
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Strategies to determine positive anti-SARS-CoV-2 memory T lymphocyte response during the evolution of an epidemic
Nel et al, Journal of Immunological Models (2024)
Products used: PepMix SARS-CoV-2 (NCAP), PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
Switching disease-modifying therapies from sphingosine-1-phosphate receptor modulators to natalizumab or dimethyl fumarate restores immune responses after SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis
Kanakura et al., Clinical Neurology and Neurosurgery (2024) - PMID: 38901377
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice
Slamaning et al., EBioMedicine (2024) - PMID: 38848648
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
SARS-CoV-2-specific immune responses converge in kidney disease patients and controls with hybrid immunity
Aguilar-Bretones et al., Vaccines (2024)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Imbalance of SARS-CoV-2-specific CCR6+ and CXCR3+ CD4+ T cells and IFN-γ + CD8+ T cells in patients with Long-COVID
Martínez-Fleta et al., Clinical Immunology (2024)
Products used: PepMix SARS-CoV-2 (NCAP), PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
Optimizing SARS-CoV-2 vaccine responses in kidney transplant recipients: an urgent need
Cheng et al., Microbiology Spectrum (2024) - PMID: 38747636
Products used: PepMix SARS-CoV-2 (Spike B.1.617.2 / Delta), SARS-CoV-2 (Spike B.1.1.529 / BA.2 / Omicron)
Modulation of innate immune response to mRNA vaccination after SARS-CoV-2 infection or sequential vaccination in humans
Hellgren et al., JCI Insight (2024)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Intranasal vaccination with an NDVvectored SARS-CoV-2 vaccine protects against Delta and Omicron challenges
Warner et al., Vaccines (2024) - PMID: 38782986
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Kinetics of pro- and anti-inflammatory spike-specific T-cell responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: A prospective longitudinal study in Japan
Kakugawa et al., Immunity & Ageing (2024)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Nasal vaccination of triple-RBD scaffold protein with flagellin elicits long-term protection against SARS-CoV-2 variants including JN.1
Li et al., Signal Transduction and Targeted Therapy (2024) - PMID: 38678055
Product used: PepMix SARS-CoV-2 (S-RBD)
COVID-19 vaccination induces distinct T-cell responses in pediatric solid organ transplant recipients and immunocompetent children
Roznik et al., Vaccines (2024)
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)
Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity
Wolz et al., Vaccines (2024)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
From Vaccination to Infection: Mechanistic Studies of Immune Responses to SARS-COV-2
Lenart, Dissertation (2024)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Immunogenicity and efficacy of VLA2001 vaccine against SARS-CoV-2 infection in male cynomolgus macaques
Galhaut et al., Communications Medicine (2024) - PMID: 38570605
Products used: PepMix SARS-CoV-2 (S-RBD), SARS-CoV-2 (NCAP)
Evaluation of T Cell Response to SARS-CoV-2 in Kidney Transplant Recipients Receiving Monoclonal Antibody Prophylaxis and the Utility of a Bivalent mRNA Vaccine Booster Dose
Bertrand et al., Microorganisms (2024)
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (NCAP), SARS-CoV-2 (NS7A), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), SARS-CoV-2 (Nsp3), CEFX Ultra SuperStim Pool
Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity
Abbasi et al., Molecular Therapy (2024)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination
Verstegen et al., Multiple Sclerosis (2024) - PMID: 38548324
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
Comparable CD8+ T‐cell responses to SARS‐CoV‐2 vaccination in single‐cell transcriptomics of recently allogeneic transplanted patients and healthy individuals
Tranter et al., Journal of Medical Virology (2024)
Product used: CEFX Ultra SuperStim Pool, PepMix SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 AP3A (ORF3a), SARS-CoV-2 NS7A, SARS-CoV-2 NS8, Pan‐SARS-CoV-2 Select, and custom PepMix
Generation of CRISPR-Cas9-edited Tacrolimus-resistant SARS-CoV-2-specific T-cells for adoptive cell therapy in transplant patients
Peter, Dissertation (2024)
Products used: PepMix HCMVA (pp65), SARS-CoV-2 peptide pools (NCAP, Spike S1, Spike S2, VEMP, VME1, AP3a, NS6, NS7a, NS7b, NS8, ORF9b, ORF10, Y14)
Development and Characterization of a Novel DC-Targeting Universal Influenza Vaccine
Olukitibi et al., Dissertation (2024)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1)
Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection
Clever et al., Viruses (2024)
Product used: PepMix SARS-CoV-2 (NCAP), SARS-CoV-2 Antigen Peptide NCAP (LALLLLDRL), Antigen Peptide IFN-gR H-2 Kb (TSYKFESV)
NFκB and NLRP3/NLRC4 inflammasomes regulate differentiation, activation and functional properties of monocytes in response to distinct SARS-CoV-2 proteins
Tsukalov et al., Nature Communications (2024) - PMID: 38453949
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1), SARS-CoV-2 (NCAP)
Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study
Reiter et al., Scientific Reports (2024) - PMID: 38438427
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Bivalent mRNA COVID vaccines elicit predominantly cross-reactive CD4+ T cell clonotypes
Sop et al., Cell Reports Medicine (2024) - PMID: 38423018
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)
Immune responses to SARS-CoV-2 mRNA vaccination in people with idiopathic CD4 lymphopenia
Rocco et al., Translational and Clinical Immunology (2024) - PMID: 38344971
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
A Gamma-adapted subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection
Coria et al., Nature Communications (2024) - PMID: 38307851
Products used: PepMix™ SARS-CoV-2 (S-RBD), PepMix™ SARS-CoV-2 (S-RBD P.1 / Gamma)
Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
Debie et al., Clinical Cancer Research (2024) - PMID: 36341493
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
Pant et al., Nature Medicine (2024) - PMID: 38195752
Products used: PepMix SARS-CoV-2 (S-RBD), CEFSX Ultra SuperStim Pool, CEFT Pool, Pan-CMV Select, HCMVA pp65, Pan-EBV Select, CEF Pool (standard)
MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans
Mayer et al., Vaccines (2024) - PMID: 38278816
Product used: CEF Pool (extended), PepMix SARS-CoV-2 (Spike Glycoprotein)
Low pre-existing endemic human coronavirus (HCoV-NL63)-specific T cell frequencies are associated with impaired SARS-CoV-2-specific T cell responses in people living with HIV
Ng'uni et al., Frontiers in Immunology (2024)
Products used: PepMix™ SARS-CoV-2 (Spike B.1.617.2 / Delta), HCoV-NL63 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.351 / Beta)
Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in mice
Cervantes-Torres et al., Applied Microbiology and Biotechnology (2024) - PMID: 38280035
Product used: PepMix™ SARS-CoV-2 (S-RBD B.1.617.2 / Delta)
Comparison of Omicron Breakthrough Infection Versus Monovalent SARS-CoV-2 Intramuscular Booster Reveals Differences in Mucosal and Systemic Humoral Immunity
Nantel et al., Mucosal Immunology (2024)
Products used: PepMix™ SARS-CoV-2 (Spike P.1 / Gamma), SARS-CoV-2 (Spike B.1.351 / Beta), SARS-CoV-2 (Spike B.1.617.2 / Delta), SARS-CoV-2 (Spike B.1.1.7 / Alpha), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
Expanded specific T cells to hypomutated regions of the SARS-CoV-2 using mRNA electroporated antigen presenting cells.
Ogando-Rivas et al., Methods and Clinical Development (2024)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (VME1), SARS-CoV-2 (VEMP), SARS-CoV-2 (NCAP)
Enhanced detection of antigen-specific T cells by a multiplexed AIM assay
Lemieux et al., Cell Rep Methods (2024) - PMID: 38228152
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), HIV-1 (GAG) Ultra, HIV-1 (POL) Ultra, HIV-1 (ENV) Ultra, HIV-1 (NEF) Ultra, HCMVA (pp65)
Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARSCoV-2
Lenart et al., Vaccines (2024) - PMID: 38245545
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity
Muñoz-Alía et al., mBio (2024) - PMID: 38193729
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
CD3-downregulation identifies T-helper-cells with superior functionality and distinct metabolism in SARS-CoV2-vaccination- and recall-antigen-specific immunity
Sattler et al., JCI Insight (2024)
Products used: PepMix™ SARS-CoV-2 (Spike B.1.1.7 / Alpha), SARS-CoV-2 Antigen Peptide Spike Fusion (SFIEDLLFNKVTLAD)
Humoral and cellular immune responses after COVID-19 vaccination of lung transplant recipients and patients on the waiting list: a 6-month follow-up
Hoek et al., Frontiers in Immunology (2024)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Protective MVA-ST Vaccination Robustly Activates T Cells and Antibodies in an Aged-Hamster Model for COVID-19
Clever et al., Vaccines (2024)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation
Binayke et al., NPJ Vaccines (2024) - PMID: 38167915
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), PepMix Pan-SARS-CoV-2 Select

References Archive

Production, purification and immunogenicity of Gag virus-like particles carrying SARS-CoV-2 components
Gashti et al., Vaccine (2023) - PMID: 38042697
Product used: PepMix SARS-CoV-2 (NCAP)
Interaction dynamics between innate and adaptive immune cells responding to SARSCoV-2 vaccination in non-human primates
Schramm et al., Nature Communications (2023) - PMID: 38042809
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Associations of myeloid cells with cellular and humoral responses following vaccinations in patients with neuroimmunological diseases
Wang et al., Nature Communications (2023) - PMID: 38007484
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Impaired Cellular and Antibody immunity after COVID-19 in Chronically Immunosuppressed Transplant Recipients
Ashokkumar et al., Journal of Surgery and Research (2023)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB2)
A Phase I/II Clinical Trial of Intradermal, Controllable Self-Replicating Ribonucleic Acid Vaccine EXG-5003 against SARS-CoV-2
Koseki et al., Vaccines (2023)
Product used: PepMix SARS-CoV-2 (S-RBD)
Efectiveness ofVSV vectored SARS‑CoV‑2 spike when administered through intranasal, intramuscular or a combination of both
Beitari et al., Scientific Reports (2023) - PMID: 38049498
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
Cross-regulation of antibody responses against the SARS-CoV-2 Spike protein and commensal microbiota via molecular mimicry
Bondareva et al., Cell Host & Microbe (2023) - PMID: 37944493
Product used: PepStar Peptide Microarray Multiwell SARS-CoV-2 Spike glycoprotein wild type + mutations
Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in mice
Barbey et al., European Journal of Pharmaceutics and Biopharmaceutics (2023) - PMID: 37774890
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
Impaired immune responses and prolonged viral replication in lung allograft recipients infected with SARS‑CoV‑2 in the early phase after transplantation
Glueck et al., Infection (2023) - PMID: 37922037
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Early humoral and cellular responses after bivalent SARS‐CoV‐2 mRNA‐1273.214 vaccination in long‐term care and retirement home residents in Ontario, Canada: An observational cohort study
Breznik et al., Journal of Medical Virology (2023) - PMID: 37822054
Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
Humoral and Cellular Immunity Are Significantly Affected in Renal Transplant Recipients, Following Vaccination with BNT162b2
Fylaktou et al., Vaccines (2023)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
SARS-CoV-2 infection establishes a stable and age-independent CD8+ T cell response against a dominant nucleocapsid epitope using restricted T cell receptors
Choy et al., Nature Communications (2023) - PMID: 37872153
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1)
Revaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patients
Ammitzbøll et al., Clinical and Experimental Rheumatology (2023) - PMID: 37877429
An interferon-integrated mucosal vaccine provides pan-sarbecovirus protection in small animal models
Yuen et al., Nature Communications (2023) - PMID: 37875475
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2
Lázaro-Gorines et al., Advanced Science (2023)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
T regulatory lymphocytes specific for SARS-CoV-2 display increased functional plasticity
Esparcia-Pinedo et al., Clinical Immunology - PMID: 37827267
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), PepMix HCMVA (pp65)
Immune Profile Determines Response to Vaccination against COVID-19 in Kidney Transplant Recipients
Stai et al., Vaccines (2023) - PMID: 37896986
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Cytokine profile of anti-spike CD4+T cells predicts humoral and CD8+T cell responses after anti-SARSCoV-2 mRNA vaccination
Tartour et al., Research Square (2023)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
An RNA-Scaffold Protein Subunit Vaccine for Nasal Immunization
Lam et al., Vaccines (2023) - PMID: 37896953
Product used: PepMix SARS-CoV-2 (S-RBD)
Selection of cross-reactive T cells by commensal and food-derived yeasts drives cytotoxic TH1 cell responses in Crohn’s disease
Martini et al., Nature Medicine (2023) - PMID: 37749331
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Enhanced Omicron subvariant cross-neutralization efficacy of a SARS-CoV-2 BA.4/5 mRNA vaccine encoding a noncleaved, nonfusogenic spike antigen
Oh et al., Research Square (2023)
Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)
Spontaneous HIV expression during suppressive ART is associated with the magnitude and function of HIVspecific CD4+ and CD8+ T cells
Dubé et al., Cell Hosts Microbe (2023) - PMID: 37708853
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment
Donhauser et al., Journal for ImmunoTherapy of Cancer - PMID: 37730271
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: A 20- month longitudinal study
Hvidt et al., Research Square (2023) - PMID: 37974069
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
SARS-CoV-2 variants of concern elicit divergent early immune responses in hACE2 transgenic mice
Fricke et al., European Journal of Immunology (2023) - PMID: 37609807
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Enhancing Anti-SARS-CoV-2 Neutralizing Immunity by Genetic Delivery of Enveloped Virus-like Particles Displaying SARS-CoV-2 Spikes
Yang et al., Vaccines (2023)
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
Intradermal administration of DNA vaccine targeting Omicron SARS‑CoV‑2 via pyro‑drive jet injector provides the prolonged neutralizing antibody production via germinal center reaction
Hayashi et al., Scientific Reports (2023) - PMID: 37563266
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults
Pasquevich et al., Nature Communications (2023)
Product used: PepMix SARS-CoV-2 (S-RBD P.1 / Gamma)
Breadth and Durability of SARS-CoV-2-Specific T Cell Responses following Long-Term Recovery from COVID-19
Dang et al., Microbiology Spectrum (2023) - PMID: 37428088
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), SARS-CoV-2 (ORF10), SARS-CoV-2 (ORF9B) Custom PepMix : SARS-CoV-2 ORF3a, ORF6, ORF7a, ORF7b, ORF8
A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation
Kimura et al., Molecular Therapy (2023) - PMID: 37403357
Product used: PepMix™ SARS-CoV-2 (Spike B.1.351 / Beta)
Immunological imprinting of humoral immunity to SARS-CoV-2 in children
Dowell et al., Nature Communications - PMID: 37386081
Product used: PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron) & Influenza A (MP1 (H3N2))
Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines
Han et al., Nature Nanotechnology (2023) - PMID: 37365276
Products used: PepMix™ SARS-CoV-2 (S-RBD)
Characterization of T cell responses to SARS-CoV-2 following infection and vaccination
Law, Dissertation (2023)
Products used: PepMix™SARS-CoV-2 (VME1), SARS-CoV-2 (VEMP), SARS-CoV-2 (NCAP) & SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
Oligosymptomatic long-term carriers of SARS-CoV-2 display impaired innate resistance but increased high-affinity anti-Spike antibodies
Montes-Cobos et al., iScience (2023)
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARSCoV-2 in Adult Patients with Immune-Mediated Inammatory Diseases
Cheung et al., Journal of Immunology (2023) - PMID: 37326480
Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)
T-Cell-Dominated Immune Response Resolves Protracted SARS-CoV-2 Infection in the Absence of Neutralizing Antibodies in an Immunocompromised Individual
Bunse et al., Microorganisms (2023) - PMID: 37375064
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
High efficacy of VLA2001 vaccine against SARSCoV-2 infection in non-human primates
Le Grand et al., Research Square (2023)
Products used: PepMix™ SARS-CoV-2 (S-RBD) & SARS-CoV-2 (NCAP)
A novel multi-antigenic parapoxvirus-based vaccine demonstrates efficacy in protecting hamsters and non-human primates against SARS-CoV-2 challenge
Reguzova et al., Research Square et al., (2023)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP)
The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus
Brzuska et al., Microbiology Spectrum (2023) - PMID: 37199661
Product used: PepMix™ SARS-CoV-2 (S-RBD)
Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy
Macková et al., Leukemia Research (2023) - PMID: 37216792
Product used: PepMix™ SARS-CoV-2 (NCAP)
Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity
Dietz et al., Communications Medicine (2023) - PMID: 37095240
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines
Hoffmann et al., Cell (2023) - PMID: 37146611
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
COVID-19 relapse associated with SARS-CoV-2 evasion from CD4+ T-cell recognition in an agammaglobulinemia patient
Morita et al., iScience (2023) - PMID: 37124420
Products used: 27 structural and non-structural PepMix SARS-CoV-2 proteins
Omicron BA.4/5 neutralization and T-cell responses in organ transplant recipients after Booster mrna vaccine: a Multicenter Cohort Study
Ferreira et al., Clinical Infectious Diseases (2023) - PMID: 36975097
Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)
Cytotoxic T Cells Targeting Spike Glycoprotein Are Associated with Hybrid Immunity to SARS-CoV-2
Phan et al., Journal of Immunology (2023) - PMID: 36961450
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP)
Humoral and cellular immunity to SARS-CoV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence on the vaccine administered
López-Cortés et al., Frontiers in Immunology (2023) - PMID: 37006309
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies
Shrivastava et al., Vaccines (2023) - PMID: 36934088
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
Immunogenicity of COVID-eVax Delivered by Electroporation Is Moderately Impacted by Temperature and Molecular Isoforms
D'Alessio et al., Vaccines (2023) - PMID: 36992261
Product used: PepMix™ SARS-CoV-2 (S-RBD)
Incorporation of SARS-CoV-2 spike NTD to RBD Protein Vaccine Improves Immunity Against Viral Variants
Montgomerie et al., IScience (2023)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Pyrimidine de novo synthesis inhibition selectively blocks effector but not memory T cell development
Scherer et al., Nature Immunology (2023)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice
Nanishi et al., Vaccines (2023)
Product used: PepMix SARS-CoV-2 (S-RBD)
Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models
Corleis et al., Nature Communications (2023)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Linear epitope mapping of the humoral response against SARS‑CoV‑2 in two independent African cohorts
Vigan-Womas et al., Scientific Reports (2023)
Product used: custom PepStar & PepSpots Peptides on Cellulose
Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A Prospective double-blind randomised hase III clinical study
Thuluva et al., MedRxiv (2023)
Product used: PepMix SARS-CoV-2 (S-RBD)
Assessment of Immunogenicity and Efficacy of CV0501 mRNA-based Omicron COVID-19 Vaccination in Small Animal Models
Roth et al., BioRxiv (2023)
Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
Safety, tolerability, and immunogenicity of a new SARS-CoV-2 recombinant Gamma variant RBD-based protein adjuvanted vaccine, used as heterologous booster in healthy adults: a Phase 1 interim report
Pasquevich et al., MedRxiv (2023)
Product used: PepMix SARS-CoV-2 (S-RBD P.1 / Gamma)
An inactivated SARS-CoV-2 vaccine induced cross-neutralising persisting antibodies and protected upon challenge in small animals
Offersgaard et al., iScience (2023)
Products used: PepMix SARS-CoV-2 (S-MUT), SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (S-RBD), SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2),
Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune modifying therapies
Klebanoff et al., MedRxiv (2023)
Products used: PepMix CEFX Ultra Superstim Pool & SARS-CoV-2 (Spike Glycoprotein)
A linear DNA encoding the SARS-CoV-2 receptor binding domain elicits potent immune response and neutralizing antibodies in domestic cats
Conforti et al., Molecular Therapy (2023)
Product used: PepMix SARS-CoV-2 (S-RBD)
The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity
Liu et al., Communications Biology (2023)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated Individuals
Emmelot et al., Viruses (2023)
Products used: custom PepMix

SARS-CoV-2 Spike-specific IFN-gamma T-cell Response After COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant
Imhof et al., Infectious Disease (2022)
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
Efficacy of mucosal vaccination using a protozoan parasite as a vehicle for antigen delivery: IgG and neutralizing response after rectal administration of LeCoVax-2, a candidate vaccine against COVID-19
Epis et al., Pharmacological Research (2022) - PMID: 36336215
Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplant recipients in the first year after COVID-19
Kirchner et al., PLoS One (2022) - PMID: 36322587
Immunodominant Linear B-Cell Epitopes of SARS-CoV-2 Spike, Identified by Sera from K18-hACE2 Mice Infected with the WT or Variant Viruses
Levy et al., Vaccines (2022) - PMID: 34650130
Immunization with 674e685 fragment of SARS-Cov-2 spike protein induces neuroinflammation and impairs episodic memory of mice
Lykhmus et al., Biochemical and Biophysical Research Communications (2022)
Treatment of Long COVID with nirmatrelvir/ritonavir and tocilizumab in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence: a case report
Visvabharathy et al., Research Square (2022)
SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod
Meyer-Arndt et al., J Neurol Neuroscurg Psychiatry (2022) - PMID: 35835468
A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2
Ilinykh et al., Vaccines (2022)
High‑resolution analysis of long‑term serum antibodies in humans following convalescence of SARS‑CoV‑2 infection
Facciuolo et al., Scientific Reports (2022)
SARS-CoV-2 mRNA vaccination fails to elicit humoral and cellular immune responses in multiple sclerosis patients receiving fingolimod
Meyer-Arndt et al., MedRxiv (2022)
Products used: PepStar SARS-CoV-2 Spike Glycoprotein Variant Collection (incl. Omicron)
Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination
Sistere-Oro et al., Frontiers in Immunology (2022)
DNA-Vaccine-Induced Immune Response Correlates with Lower Viral SARS-CoV-2 Titers in a Ferret Model
Compagnone et al., Vaccines (2022) - PMID: 35893826
SARS-CoV-2 Vaccine-Induced Antibody and T-Cell Response in SARS-CoV-1 Survivors
Duan et al., Cell Reports (2022)
The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and qualityunder TNFα blockade
Geisen et al., Journal of Medical Virology (2022) - PMID: 35945627
Secreted heat shock protein gp96-Ig and OX40L-Fc combination vaccine enhances SARS-CoV-2 Spike (S) protein-specific B and T cell immune responses
Padula et al., Vaccine: X (2022) - PMID: 35936992
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SU1 & SU2)
Analysis of the Specific Immune Response after the Third Dose of mRNA COVID-19 Vaccines in Organ Transplant Recipients: Possible Spike-S1 Reactive IgA Signature in Protection from SARS-CoV-2 Infection
Miele et al., Microorganisms (2022)
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SU1 & SU2) & SARS-CoV-2 NCAP
mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
Nanishi et al., Communications Biology (2022)
SARS-CoV-2-specific CD4+ T cell longevity correlates with Th17-like phenotype
Terahara et al., iScience (2022) - PMID: 35992306
SARS‑CoV‑2‑reactive IFN‑γ‑producing CD4+ and CD8+T cells in blood do not correlate with clinical severity in unvaccinated critically ill COVID‑19 patients
Olea et al., Scientific Reports (2022) - PMID: 35995830
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response
Stort et al., Oncoimmunology (2022)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment
Su et al., ESMO Open (2022)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation
Azamor et al., Viruses (2022) - PMID: 36146723
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors
Lu et al., Clinical Immunology (2022)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Comparison of the Immune Responses to COVID-19 Vaccines in Bangladeshi Population
Sarker et al., Vaccines (2022)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Comparison between enzyme‐linked immunospot assay and intracellular cytokine flow cytometry assays for the evaluation of T cell response to SARS‐CoV‐2 after symptomatic COVID‐19
Villemonteix et al., Immunity, Inflammation and Disease (2022)
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP)
Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models
Hajnik et al., Science Translational medicine (2022) - PMID: 36103514
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection
Ao et al., Journal of Virology (2022) - PMID: 36069551
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1)
SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN, induces robust humoral and cellular immunity in mice and non-human primates
Alimohammadi et al., Vaccines (2022) - PMID: 36056015
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Ablation of CD8+ T cell recognition of an immunodominant epitope in SARS-CoV-2 Omicron variants BA.1, BA.2 and BA.3
Swaminathan et al., Nature Communications
Products used: PepMix SARS-CoV-2 (NCAP), SARS-CoV-2 (NS6), SARS-CoV-2 (NS7A), SARS-CoV-2 (NS7B), SARS-CoV-2 (NS8), SARS-CoV-2 (ORF9B), SARS-CoV-2 (ORF10), SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), SARS-CoV-2 (Y14)
Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection
Khatamzas et al., Nature Communication (2022)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Evidence of premature lymphocyte aging in people with low anti-spike antibody levels after BNT162b2 vaccination
Huang et al., iScience (2022)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens
Hielscher et al., Journal of Clinical Virology (2022) - PMID: 36279695
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Immune Response after the Fourth Dose of SARS-CoV-2 mRNA Vaccine Compared to Natural Infection in Three Doses’ Vaccinated Solid Organ Transplant Recipients
Busà et al., Vaccines (2022) - PMID: 36298854
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP) and CEFX Ultra SuperStim Pool
Proinflammatory Innate Cytokines and Distinct Metabolomic Signatures Shape the T Cell Response in Active COVID-19
Binayke et al., Vaccines (2022) - PMID: 36298628
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose
Belik et al., Research Square (2022)
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron), and SARS-CoV-2 (Spike B.1.1.529 / BA.2 / Omicron)
Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 Vaccine
Lam et al., ACS Nano (2022)
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults
Palacios-Pedrero et al., Nature Aging (2022)
Product used: PepMix SARS-CoV-2 (NCAP)
Humoral and Cellular Responses to a Delayed Fourth SARS-CoV-2 mRNA-Based Vaccine in Weak Responders to 3 Doses Kidney Transplant Recipients
Del Bello et al., Vaccines (2022) - PMID: 36146517
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses
Lenart et al., Molecular Therapy (2022)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
A Tale Of T ale Of Two Transgenes: Aa ansgenes: Aav-Dystr v-Dystrophin And Aa ophin And Aav-Spike Reveal Common Themes For Gene Therapy And Vaccines
Greer, Dissertation (2022)
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein) and SARS-CoV-2 (Spike B.1.1.7 / Alpha)
Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern
Akache et al., Vaccines (2022)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Analysis of the humoral and cellular response after the third COVID-19 vaccination in patients with autoimmune hepatitis
Hartl et al., Liver International (2022) - PMID: 35840342
Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination
Tang et al., Science Immunology (2022) - PMID: 35857583
Robust SARS-COV-2-specific T-cell immune memory persists long-term in immunocompetent individuals post BNT162b2 double shot
Papadopoulou et al., Heliyon (2022) - PMID: 35815135
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
A novel SARS-CoV-2 subunit vaccine engineered on an immune-activating platform technology
Quinlan et al., Human Vaccines & Immunotherapeutics (2022) - PMID: 35801956
Product used: PepMix SARS-CoV-2 (Spike-RBD)
Safety and immunogenicity of intramuscular, single- dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double- blind, placebo-controlled, dose-ranging trial
Robbins et al., The Lancet (2022)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
Longitudinal T Cell Responses against Ancestral, Delta, and Omicron SARS-CoV-2 Variants determined by Rapid Cytokine Release Assay in Whole Blood
Oliver et al., Immunohorizons (2022) - PMID: 35750357
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SU1 & SU2), SARS-CoV-2 (Spike B.1.617/Delta), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
Long-Lived Immunity in SARS-CoV-2-Recovered Children and Its Neutralizing Capacity Against Omicron
Sieber et al., Frontiers in Immunology (2022) - PMID: 35663948
Product used: PepMix SARS-CoV-2 (VME1), SARS-CoV-2 (VEMP), SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
T-cell proliferation assay for the detection of SARS-CoV-2-specific T-cells
Chu et al., Clinical Chimica Acta (2022) - PMID: 35690083
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1)
A DNA vaccine candidate delivered by an electroacupuncture machine provides protective immunity against SARS-CoV-2 infection
Tzeng et al., Vaccines (2022)
Chimeric Virus-like Particle-Based COVID-19 Vaccine Confers Strong Protection against SARS-CoV-2 Viremia in K18-hACE2 Mice
Kaewborisuth et al., Vaccines (2022)
SARS-CoV-2 OmicronBA.1 variant breakthrough infections in nursing home residentsafter an homologousthird dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection
Torres et al., Journal of Medical Virology (2022)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
Functional Analysis of Human and Feline Coronavirus Cross-Reactive Antibodies Directed Against the SARS-CoV-2 Fusion Peptide
Vanderheijden et al., Frontiers in Immunology (2022) - PMID: 35069571
Durable immunogenicity, adaptation to emerging variants and low dose efficacy of AAV-based COVID19 platform in macaques
Zabaleta et al., Molecular Therapy (2022)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
Enhanced Humoral Immune Response After COVID-19 Vaccination in Elderly Kidney Transplant Recipients on Everolimus Versus Mycophenolate Mofetil–containing Immunosuppressive Regimens
de Boer et al., Translantation (2022) - PMID: 35546527
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infection
Richardson et al., PLoS One (2022) - PMID: 35468147
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.7 / Alpha), SARS-CoV-2 (Spike B.1.351 / Beta), SARS-CoV-2 (Spike P.1 / Gamma), SARS-CoV-2 (Spike B.1.617.2 / Delta)
Two DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian hamsters
Babuadze et al., NPJ Vaccines (2022) - PMID: 35474311
Product used: PepMix™ SARS-CoV (Spike Glycoprotein)
Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2 Specific T cell therapy products
Durkee-Shock et al., Molecular Therapy: Methods & Clinical Development (2022)
Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
Cabeza et al., Neurology: Neuroimmunology & Neuroinflammation - PMID: 35523569
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
Children and Adults With Mild COVID-19: Dynamics of the Memory T Cell Response up to 10 Months
Kaaijk et al., Frontiers in Immunology (2022)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), HCoV-OC43 (Spike Glycoprotein)
Strong peak immunogenicity but rapid antibody waning following third vaccine dose in elderly residents of care homes
Tut et al., Research Square (2022)
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
Discordant antibody and T cell responses to the SARS-CoV-2 Omicron variant in COVID-19 mRNA vaccine recipient
Woldemeskel et al., Clinical Infectious Diseases (2022) - PMID: 35438751
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (S-RBD B.1.1.529 / Omicron)
USA SARS-CoV-2 Epsilon Variant: Though Highly Transmissible has an Adjusted Muted Host T-Cell Response
Plummer et al., Clinical Infectious Diseases (2022) - PMID: 35438777
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (Spike B.1.429 / Epsilon)
mRNA booster vaccination protects extremely aged mice against the SARS-CoV-2 Omicron variant
Dowling et al., Research Square (2022)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (S-RBD B.1.1.529 / Omicron)
Viral Evolution and Immunology of SARS-CoV-2 in a Persistent Infection after Treatment with Rituximab
van der Moerden et al., Viruses (2022)
Dynamics of SARS-CoV-2-Spike-reactive antibody and T-cell responses in chronic kidney disease patients within three months after COVID-19 full vaccination
Panizo et al., Clinical Kidney Journal (2022)
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial
Pannus et al., MedRxiv (2022)
Temporal changes in T cell subsets and expansion of cytotoxic CD4+ T cells in the lungs in severe COVID-19
Kaneko et al., Clinical Immunology (2022) - PMID: 35364330
T cell response against SARS-CoV-2 persists after one year in patients surviving severe COVID-19
Venet et al., EBioMedicine (2022) - PMID: 35349827
CD4+ T Cell Dysfunction in Severe COVID-19 Disease is TNFalpha/TNFRI-Dependent
Popescu et al., American Journal of Respiratory Critical Care Medicine - PMID: 35348444
The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors
Kroemer et al., Front Public Health (2022) - PMID: 35372242
High antibody and reduced cellular response in children up to one year after SARS-CoV-2 infection
Jacobsen et al., Research Square (2022)
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study
Lim et al., Nature Cancer (2022) - PMID : 35332334
Self-amplifying mRNA SARS-CoV-2 vaccines raise cross-reactive immune response to variants and prevent infection in animal models
Palladino et al., Methods and Clinical Development (2022)
Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine
Gallais et al., Frontiers in Immunology (2022) - PMID: 35281046
SARS‐CoV‐2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease
Duengelhoef et al., United European Gastroenterol Journal (2022) - PMID: 35289983
Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 response
Renaudineau et al., Clinical Immunology (2022) - PMID: n.a.
Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
Sheng et al., Journal of the Formosan Medical Association (2022) - PMID: 35305895
Modular capsid decoration boosts adenovirus vaccine-induced humoral and cellular immunity against SARS-CoV-2
Dicks et al., BioRxiv (2022)
SARS-CoV- 2 (COVID- 19)-specific T cell and B cell responses in convalescent rheumatoid arthritis: Monozygotic twins pair case observation
Arruda et al., Immunology (2022) - PMID: 35212005
Products used: PepMix™ SARS-CoV-2 (NCAP) & SARS-CoV-2 (Spike Glycoprotein)
Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine
Abravanel et al., Vaccines (2022)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
Three-month follow-up of heterologous vs homologous third vaccination in kidney transplant recipients
Heinzel et al., MedRxiv (2022)
Performance comparison of a fow cytometry immunoassay for intracellular cytokine staining and the QuantiFERON® SARS-CoV-2test for detection and quantifcation of SARS-CoV-2-Spike-reactiveIFN-γ-producing T cells after COVID-19 vaccination
Tormo et al., European Journal of Clinical Microbiology & Infectious Diseases (2022) - PMID: 35165804
SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variant
Panikkar et al., Pathogens (2022) - PMID: 35157735
T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individuals
Vivek Naranbhai et al., MedRxiv (2022) - PMID: 35018386
Innate and adaptive immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in elderly people
Joana Vitallé et al., medRxiv (2022) - PMID: n.a.
Temporary hold of mycophenolate boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients
Eva Schrezenmeier et al., MedRxiv (2022)
Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents
Nina Koerber et al., Nature Communications (2022)
Persistent T-Cell Reactivity in a Seronegative Patient after SARS-CoV-2 Infection and One Vaccination
Nico Andreas et al., Vaccines (2022)
Development of an effective immune response in adults with Down Syndrome 2 after SARS-CoV-2 vaccination
Laura Esparcia-Pinedo et al., MedRxiv (2022)
Antibody and T cell responses to SARS-CoV-2 mRNA vaccines during maintenance therapy for immune-mediated inflammatory diseases
Dayam et al., MedRxiv (2022)
Infection or a third dose of mRNA vaccine elicit neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients
Charmetant et al., Science Translational Medicine (2022) - PMID: 35103481
Concordance of B and T cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19
Österdahl et al., MedRxiv (2022)
Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice
Lázaro-Frías et al., Vaccines (2022)
mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron
Gagne et al., BioRxiv (2022)
Effectiveness and durability of the mRNA vaccine-induced SARSCoV-2-specific humoral and cellular immunity in severe asthma patients on biological therapy
Prodrazil et al., MedRxiv (2022)
Limited Recognition of Highly Conserved Regions of SARS-CoV-2
Swaminathan et al., Microbiology Spectrum (2022) - PMID: 35196796
Assessment of humora land cellular immune responses to SARSCoV-2 vaccination (BNT162b2) inimmunocompromised renal allograft recipients
Zhang et al., Transplant Infectious Diseases (2022)
Tacrolimus-resistant SARS-CoV-2-specific T-cell products to prevent and treat severe COVID-19 in immunosuppressed patients
Peter et al., Molecular Therapy (2022)
BNT162b2 Vaccine Induces Neutralizing Antibodies and Poly-Specific T Cells in Humans
Ugur Sahin et al., Nature (2021)
Cross-Reactive CD4+ T Cells Enhance SARS-CoV-2 Immune Responses Upon Infection and Vaccination
Loyal et al, Science (2021)
Protection Against SARS-CoV-2 Beta Variant in mRNA-1273 Vaccine–Boosted Nonhuman Primates
Kizzmekia S. Corbett et al., Science, (2021)
Children Develop Strong and Sustained Cross-Reactive Immune Responses Against Spike Protein Following SARS-CoV-2 Infection, With Enhanced Recognition of Variants of Concern
Alexander C. Dowell et.al., medRxiv (2021)
Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2
Krystle K.Q. Yu et.al., JCI Insight (2021) - PMID: 33621211
Targeting SARS-CoV-2 Receptor-Binding Domain to Cells Expressing CD40 Improves Protection to Infection in Convalescent Macaques
Romain Marlin et.al., Nature Communications (2021)
Longitudinal Analysis of Human Memory T-Cell Response according to the Severity of Illness up to 8 Months after SARS-CoV-2 Infection
Chang Kyung Kang et.al., The Journal of Infectious Diseases (2021) - PMID: 33755725
Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
Jianmin Zuo et.al., Nature (2021) - PMID: 33674800
SARS-CoV-2 Spike Protein Arrested In The Closed State Induces Potent Neutralizing Responses
George W. Carnell et.al., bioRxiv (2021)
First Report Demonstrating The Safety And Immunogenicity Of The SARS-COV-2 BNT162b1 mRNA Vaccine In Younger And Older Chinese Adults: A Randomized, Placebo-Controlled, Observer-Blind Phase I Study
Fengcai Zhu et.al., Research Square (2021)
Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept
Nathalie Chavator et al., Transplantation, (2021)
SARS-CoV-2 Specific Memory T Cell Epitopes Identified in COVID-19-Recovered Subjects
Juan Zhao et al., Virus Res, (2021)
SARS-CoV2 Mutant-Specific T Cells and Neutralizing Antibodies After Vaccination and up to 1 Year After Infection
Richardson, J.R. et al., ISAR Bioscience, (2021)
COVID-19 Subunit Vaccine with a Combination of TLR1/2 and TLR3 Agonists Induces Robust and Protective Immunity
Soo-Kyung Jeong et al., Vaccines, (2021)
Impairment of CD4+ T and Memory B Cell Responses but Normal Memory CD8+T-Cell Activation on Crohn’s Disease after COVID-19 Vaccination: A Twin Case
Fabiana Gil-Melgaço et al., Viruses, (2021)
Weak Immunogenicity of SARS-CoV-2 Vaccine in Patients With Hematologic Malignancies
Florent Malard et al., Blood Cancer J, (2021)
CD4+ T Cells of Prostate Cancer Patients Have Decreased Immune Responses to Antigens Derived From SARS-CoV-2 Spike
Pavla Taborska et al., Front Immunol, (2021)
T Cell–Mediated Response to SARS-CoV-2 in Liver Transplant Recipients With Prior COVID-19
Mario Fernández-Ruiz et al., Am J Transplant, (2021)
Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) Study: an Observational Cohort Study of SARS-CoV-2 Infection and Vaccination in Healthcare Workers
Jackson, B.M. et al., BMC Infect Dis, (2021)
Cellular Immunity Predominates Over Humoral Immunity After Homologous and Heterologous mRNA and Vector-Based COVID-19 Vaccine Regimens in Solid Organ Transplant Recipients
Tina Schmidt et al., Am J Translplant, (2021)
The Legacy of Maternal SARS-CoV-2 Infection on the Immunology of the Neonate
Sarah Gee et al., Nat Immunol, (2021)
A Single-Cycle Influenza A Virus-Based SARS-CoV-2 Vaccine Elicits Potent Immune Responses in a Mouse Model
Surapong Koonpaew et al., Vaccines, (2021)
Impact of Multiple Sclerosis Disease-Modifying Therapies on SARS-CoV-2 Vaccine-Induced Antibody and T Cell Immunity
Sabatino, J.J. et al., MedRxiv, (2021)
Complete Protection of Nasal and Lung Airways Against SARS-CoV-2 Challenge by Antibody Plus Th1 Dominant N- and S-Specific T-Cell Responses to Subcutaneous Prime and Thermally-Stable Oral Boost Bivalent hAd5 Vaccination in an NHP Study
Elizabeth Gabitzsch et al., BioRxiv, (2021)
The Evaluation of Novel Oral Vaccines Based on Self-Amplifying RNA Lipid Nanparticles (saRNA LNPs), saRNA Transfected Lactobacillus Plantarum LNPs, and saRNA Transfected Lactobacillus Plantarum to Neutralize SARS-CoV-2 Variants Alpha and Delta
Reza Keikha et al., Sci Rep, (2021)
Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge
King R.G. et al., Vaccines, (2021)
T-Cell and Antibody Immunity After COVID-19 mRNA Vaccines in Healthy and Immunocompromised Subjects-An Exploratory Study
Rakesh Sindhi et al., MedRxiv, (2021)
SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity
Ji Yeun Kim et al., Am J Trop Med Hyg, (2021)
Implementation of Adenovirus-Mediated Pulmonary Expression of Human ACE2 in HLA Transgenic Mice Enables Establishment of a COVID-19 Murine Model for Assessment of Immune Responses to SARS-CoV-2 Infection
Theodor Chitlaru et al., Pathogens, (2021)
Dynamics of Antibody Response to BNT162b2 Vaccine After Six Months: a Longitudinal Prospective Study
Naaber, Paul et al., Lancet Reg Health Eur, (2021)
Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial
Punnee Pitisuttihum et al., MedRxiv, (2021)
Protracted yet Coordinated Differentiation of Long-Lived SARS-CoV-2-Specific CD8+ T Cells During COVID-19 Convalescence
Tongcui Ma et al., BioRxiv, (2021)
SARS-Cov-2 Spike Protein Fragment 674–685 Protects Mitochondria From Releasing Cytochrome c in Response to Apoptogenic Influence
Olena Kalashnyk et al., Biochem Biophys Res Commun, (2021)
CD8+PD-L1+CXCR3+ Polyfunctional T Cell Abundances Are Associated With Survival in Critical SARS-CoV-2–Infected Patients
Lucille Adam et al., JCI Insight, (2021)
Protective Antibodies Elicited by SARS-CoV-2 Spike Protein Vaccination are Boosted in the Lung After Challenge in Nonhuman Primates
Joseph R. Francica et al., Sci Transl Med, (2021)
Profiling SARS-CoV-2 HLA-I Peptidome Reveals T Cell Epitopes From Out-of-Frame ORFs
Shira Weingarten-Gabbay et al., Cell, (2021)
A Short Corticosteroid Course Reduces Symptoms and Immunological Alterations Underlying Long-COVID
Alberto Utrero-Rico et al., Biomedicines, (2021)
COVID-19 Vaccine mRNA-1273 Elicits a Protective Immune Profile in Mice That is not Associated With Vaccine-Enhanced Disease Upon SARS-CoV-2 Challenge
DiPiazza, A.T. et al., Immunity, (2021)
An Enveloped Virus-Like Particle Vaccine Expressing a Stabilized Prefusion form of the SARS-CoV-2 spike Protein Elicits Highly Potent Immunity
Anne-Catherine Fluckiger et al., Vaccine, (2021)
Intranasal Plus Subcutaneous Prime Vaccination With a Dual Antigen COVID-19 Vaccine Elicits T-Cell and Antibody Responses in Mice
Adrian Rice et al., Sci Rep, (2021)
Change in Symptoms and Immune Response in People with Post-Acute Sequelae of SARS-Cov-2 Infection (PASC) After SARS-Cov-2 Vaccination
Daisy Massay et al., MedRxiv, (2021)
Evolution of SARS-CoV-2 Immune Responses in Nursing Home Residents Following Full Dose of the Comirnaty® COVID-19 Vaccine
Giménez, E. et al., J Infect (2021)
Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera
Vidal, S-J. et al., J Virol, (2021)
Preserved T-cell Response in anti-CD20 Treated Multiple Sclerosis Patients Following SARS-CoV-2 Vaccination
Simon Faissner et al., Res Square, (2021)
Durable T cell responses contrast with faster antibody waning in BNT162b2-vaccinated elderly at 6 month
Laurent Renia et al., Res Square, (2021)
SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses
Joshua M. Carmen et al., Vaccines, (2021)
A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates
M. Gordon Joyce et al., Science Translational Medicine
SARS-CoV-2-Specific Cell-Mediated Immunity in Kidney Transplant Recipients Recovered From COVID-19
Mario Fernández-Ruiz et al., Transplantation, (2021)
SARS-CoV-2 Vaccination in Rituximab-Treated Patients: B Cells Promote Humoral Immune Responses in the Presence of T-Cell-Mediated Immunity
Daniel Mrak et al., Ann Rheum Dis, (2021)
Comorbid Illnesses are Associated With Altered Adaptive Immune Responses to SARS-CoV-2
Krystle Kq Yu et al., JCI Insight, (2021)
Longitudinal Analysis of Human Memory T-Cell Response According to the Severity of Illness up to 8 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Chang Kyung Kang et al., J Infect Dis, (2021)
Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance and Cognate Cross-Reactivity
Alexander A. Lehmann et al., Front Immunology, (2021)
Identification of Conserved SARS-CoV-2 Spike Epitopes That Expand Public cTfh Clonotypes in Mild COVID-19 Patients
Xiuyuan Lu et al., J Exp Med, (2021)
Effectiveness of ChAdOx1 nCoV-19 Vaccine Against SARS-CoV-2 Infection During the Delta (B.1.617.2) Variant Surge in India: a Test-Negative, Case-Control Study and a Mechanistic Study of Post-Vaccination Immune Responses
Ramachandran Thiruvengadam et al., Lancet Infect Dis, (2021)
Acute Exercise Increases Immune Responses to SARS CoV-2 in a Previously Infected Man
Baker, F. L. et al., Brain Behav Immun Health (2021)
Generation of Glucocorticoid-Resistant SARS-CoV-2 T Cells for Adoptive Cell Therapy
Basar et al, Cell Reports (2021)
Peptide microarray based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development
Holenya et a al, Eur J Immunol (2021)
Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine and SARS-CoV-2 Infection in Lung Transplant Recipients
Havlin et al, Journal of Heart and Lung Transplantation (2021)
COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice
García-Arriaza et al, Journal of Virology (2021)
Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates
Francica et al, bioRxiv (2021)
Impaired Anti-SARS-CoV-2 Humoral and Cellular Immune Response Induced by Pfizer-BioNTech BNT162b2 mRNA Vaccine in Solid Organ Transplanted Patients
Miele et al, American Journal of Transplantation (2021)
Therapeutic Antibodies, Targeting the SARS-CoV-2 Spike N-Terminal Domain, Protect Lethally Infected K18-hACE2 Mice
Noy-Porat et al, iScience (2021)
CD8+ T Cells Specific for an Immunodominant SARS-CoV-2 Nucleocapsid Epitope Cross-React With Selective Seasonal Coronaviruses
Lineburg et al, Immunity (2021)
Prime hAd5 Spike plus Nucleocapsid Vaccination Induces Ten-Fold Increases in Mean T-Cell Responses in Phase 1 Subjects that are Sustained Against Spike Variants
Sieling et al, medRxiv (2021)
SARS-CoV-2 Mutations in MHC-I-Restricted Epitopes Evade CD8+ T Cell Responses
Agerer et al, Science Immunology (2021)
Preclinical Evaluation of a SARS-CoV-2 mRNA Vaccine PTX-COVID19-B
Liu et al, bioRxiv (2021)
A Lymph Node-Targeted Amphiphile Vaccine Induces Potent Cellular and Humoral Immunity to SARS-CoV-2
Steinbuck et al, Sci Adv. (2021)
Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope
Makdasi et al, Viruses (2021)
SARS-CoV-2 Spike Glycoprotein Vaccine Candidate NVX-CoV2373 Immunogenicity in Baboons and Protection in Mice
Tian et al, Nat Commun. (2021)
Safety and Immunogenicity of the SARS-CoV-2 BNT162b1 mRNA Vaccine in Younger and Older Chinese Adults: a Randomized, Placebo-Controlled, Double-Blind Phase 1 Study
Li et al, Nat Med. (2021)
BNT162b Vaccines Protect Rhesus Macaques From SARS-CoV-2
Vogel et al, Nature. (2021)
Older Adults Lack SARS CoV-2 Cross-Reactive T Lymphocytes Directed to Human Coronaviruses OC43 and NL63
Saletti et al, Sci Rep. (2021)
SARS-CoV-2 Variants of Concern Partially Escape Humoral but not T-Cell Responses in COVID-19 Convalescent Donors and Vaccinees
Geers et al, Sci Immunol. (2021)
COVID-19 Immune Signatures Reveal Stable Antiviral T Cell Function Despite Declining Humoral Responses
Bonifacius et al, Nat Commun. (2021)
IL-33 Expression in Response to SARS-CoV-2 Correlates With Seropositivity in COVID-19 Convalescent Individuals
Stanczak et al, Nat Commun. (2021)
A Highly Specific Assay for the Detection of SARS-CoV-2-Reactive CD4 + and CD8 + T Cells in COVID-19 Patients
Zelba et al, J Immunol. (2021)
SARS-CoV-2-Reactive T Cells in Healthy Donors and Patients With COVID-19
Braun et al, Nature (2021)
Functional Characterization of CD4+ T Cell Receptors Crossreactive for SARS-CoV-2 and Endemic Coronaviruses
Dykema et al, J Clin Invest. (2021)
A Single-Dose Live-Attenuated YF17D-Vectored SARS-CoV-2 Vaccine Candidate
Sanchez-Felipe et al, Nature (2021)
SARS-CoV-2 Protein Subunit Vaccination of Mice and Rhesus Macaques Elicits Potent and Durable Neutralizing Antibody Responses
Mandolesi et al, Cell Reports Medicine (2021)
SARS-CoV-2 mRNA Vaccine BNT162b2 Elicited a Robust Humoral and Cellular Response Against SARSCoV-2 Variants
Lilleri et al, Research Square (2021)
SARS-CoV-2 Spike Protein Stabilized in The Closed State Induces Potent Neutralizing Responses
Carnell et al, J Virol (2021)
Robust SARS-CoV-2-specific T Cell Immunity is maintained at 6 Months Following Primary Infection
Zuo et al, Nature (2021)
First Report Demonstrating the Safety and Immunogenicity of the SARS-COV-2 BNT162b1 mRNA Vaccine in Younger and Older Chinese Adults: A Randomized, Placebo-Controlled, Observer-Blind Phase I Study
Zhu et al, Research Square (2021)
1IL-2 and IFN-γ are Biomarkers of SARS-CoV-2 Specific Cellular Response in Whole Blood Stimulation Assays
Pérez-Cabezas et al, medRxiv (2020)
Adaptive Immune Responses to SARS-CoV-2 in Recovered Severe COVID-19 Patients
Olea et al, medRxiv (2020)
Persistent Cellular Immunity to SARS-CoV-2 Infection
Breton et al, bioRxiv (2020)
Deconvoluting the T cell response to SARS-CoV-2: specificity versus chance- and cognate cross-reactivity
Lehmann et al, bioRxiv (2020)
BNT162b2 Induces SARS-CoV-2-Neutralising Antibodies and T cells in Humans
Sahin et al, medRxiv (2020)
Convalescent Plasma Therapy for B-Cell Depleted Patients With Protracted COVID-19 Disease
Hueso et al, Blood (2020)
Divergent SARS‐CoV‐2‐Specific T and B Cell Responses in Severe but Not Mild COVID‐19 Patients
Oja et al, European Journal of Immunology (2020)
mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents
Rauch et al, bioRxiv (2020)
T Cell and Antibody Responses to SARS-CoV-2: Experience From a French Transplantation and Hemodialysis Center During the COVID-19 Pandemic
Candon et al, Am J Transplant (2020)
Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without Seroconversion
Gallais et al, Emerg Infect Dis (2020)
A Glimpse Into the Diverse Cellular Immunity Against SARS-CoV-2
Chang et al, Research Square (2020)
Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and 2 non-human primates
Kalnin et al, bioRxiv (2020)
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in Older Adults
Anderson et al, NEJM (2020)
Divergent SARS-CoV-2-specific T and B cell Responses in Severe but Not Mild COVID-19
Oja et al, bioRxiv (2020)
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Corbett et al, New England J of Med (2020)
Presence of SARS-CoV-2 reactive T cells in COVID-19 Patients and Healthy Donors
Braun et al, Nature (2020)
Single-shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques
Mercado et al, Nature (2020)
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
Corbett et al, bioRxiv (2020)
Data, Reagents, Assays and Merits of Proteomics for SARS-CoV-2 Research and Testing
Zecha et al, Mol Cell Proteomics (2020)
A Longitudinal Study of Immune Cells in Severe COVID-19 Patients
Payen et al, medRXiv (2020)
SARS-CoV-2-Specific T cells Exhibit Unique Features Characterized by Robust Helper Function, Lack of Terminal Differentiation, and High Proliferative Potential
Neidleman et al, bioRxiv (2020)
Generation of SARS-CoV-2 S1 Spike Glycoprotein Putative Antigenic Epitopes in vitro by Intracellular Aminopeptidases
Stamatakis et al bioRxiv (2020)
Self-Amplifying RNA SARS-CoV-2 Lipid Nanoparticle Vaccine Candidate Induces High Neutralizing Antibody Titers in Mice
McKay et al, Nature (2020)
An mRNA Vaccine Against SARS-CoV-2 — Preliminary Report
Jackson et al, New England J of Med (2020)
SARS‐CoV‐2‐Reactive Interferon‐γ‐producing CD8+ T cells in Patients Hospitalized with Coronavirus Disease 2019
Giminez et al, J Med Vir (2020)
Concurrent Human Antibody and TH1 type T-cell Responses 2 Elicited by a COVID-19 RNA Vaccine
Sahin et al, medRXiv (2020)

Further references

Peptide Tools to Study SARS-CoV-2 and Its Variants

Applications of SARS-CoV-2 Peptide Tools

Expanding Beyond SARS-CoV-2: Peptides for Other Coronaviruses

Advancing Research with High-Quality SARS-CoV-2 Peptide Pools

JPT's SARS-CoV-2 Peptide Formats

Cellular Immunity

Humoral Immunity

Clinical Immune Monitoring & Cell Therapy

Proteomics

Find SARS-CoV-2 Peptide variants

Alpha B.1.1.7

Beta B.1.351

Gamma P.1

Delta B.1.617.2

Epsilon B.1.429

Kappa B.1.617.1

Lambda C.37

Omicron BA.1

Omicron BA.2

Omicron BA.4/5

Omicron BA.2.75

Omicron BA.2.75.2

Omicron BF.7

Omicron BQ.1.1

Omicron XBB.1.5

Omicron EG.5.1

Omicron BA.2.86

Omicron JN.1

Publications

References 2024

References Archive

Application Notes